"Neuroleptic malignant syndrome" (NMS) derives from the French "syndrome malin des neuroleptiques" and was first described in 1960 by Delay [1] and colleagues in association with haloperidol.

Yet, clinicians treating persons with autism continue to prescribe older neuroleptic agents targeting ... of tardive dyskinesia and neuroleptic malignant syndrome. This article presents a model ...

neuroleptic malignant syndrome and hypercatabolic syndrome. This important new series arises from a coordinated programme of the International Programme on Chemical Safety (IPCS) (ILO/UNEP/WHO) and ...

Since the severe, life-threatening forms of catatonia are infrequent, this book will serve as an excellent source for consultation when faced with neuroleptic malignant syndrome, delirious mania, ...

Oliver McGowan died after contracting Neuroleptic Malignant Syndrome in hospital The consultant who gave a teenager anti-psychotic drugs that have been linked to his death said she "might have ...

Patients may develop with neuroleptic malignant syndrome (NMS) with the following symptoms: body heat, rigid muscles, mental disorder, fast or irregular heartbeat and sweating; if it is so consult ...

Caplyta is not approved to treat dementia. A rare but deadly health condition called neuroleptic malignant syndrome may happen. Call your health care provider right away if you have a high fever ...

Discontinue immediately and treat appropriately if neuroleptic malignant syndrome occurs. Seizure disorder. Bone-marrow depression. Narrow-angle glaucoma. Prostatic hypertrophy. Stenosing peptic ...

GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-yearStrong cumulative ...

Neuroleptic Malignant Syndrome (NMS). Do not lower your dose or stop taking amantadine without talking to your healthcare provider. Stopping amantadine too quickly may cause a serious side effect ...

neuroleptic malignant syndrome. <6months: not recommended. ≥6months: Severe behavior disorders: 0.25mg/lb IM every 6–8 hrs if needed. Tetanus: 0.25mg/lb IM or IV (see literature) every 6–8 hrs.

Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing ...